<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02299349</url>
  </required_header>
  <id_info>
    <org_study_id>13055-13-034</org_study_id>
    <nct_id>NCT02299349</nct_id>
  </id_info>
  <brief_title>Bupivacaine Liposome Suspension Versus a Concentrated Multi Drug Periarticular Injection</brief_title>
  <official_title>Bupivacaine Liposome Suspension Versus a Concentrated Multi Drug Periarticular Injection in 70 Patients Undergoing Total Knee Arthroplasty Without Femoral Nerve Block: a Double-blinded, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TriHealth Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TriHealth Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite a robust multimodal pain management regimen, patients undergoing total knee
      arthroplasty (TKA) continue to report low satisfaction with postoperative pain management.
      Patient satisfaction further declines with any adverse event such as a drug reaction to
      neuroleptic medications or a patient fall due to a femoral nerve block. A new method of pain
      management throughout the hospital experience is warranted to improve patient satisfaction
      and the possibility of related adverse events. The purpose of this study is to examine if
      there is a difference in post operative pain and morphine (MSO4) total consumption for
      hospitalized TKA patients without femoral nerve block receiving an intra-operative
      periarticular injection of bupivacaine liposome suspension versus a concentrated multi drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The void in the literature is that while multimodal pain management reduces postoperative
      pain in the majority of TKA patients6-14, too many are still dissatisfied with overall pain
      control13 and adverse drug reactions (dizziness and somnolence) to neuroleptic medications15.
      Additionally, postoperative falls are greater with femoral nerve blocks16, and new
      neurological symptoms are associated with the block17. Bupivacaine liposome suspension
      periarticular injection has large scale national anecdotal support for TKA pain control with
      avoidance of regional block adversity. There is one recent randomized control trial in TKA
      patients favorably comparing periarticular injection with bupivacaine liposome suspension
      versus bupivacaine hydrochloride (HCL)5. To date the clinical use and published evidence most
      robustly supports bupivacaine liposome suspension in patients undergoing bunionectomy or
      hemorrhoidectomy. Additionally, in preparation for shorter hospital stays for total joint
      arthroplasty, a more effective and better tolerated pain management solution is needed.

      Hypothesis Statement:

      Hospitalized TKA patients without a pre-operative femoral nerve block will experience
      improved postoperative pain control and less MSO4 equivalence consumption when receiving an
      injection of bupivacaine liposome suspension versus concentrated multi drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Scores (Visual Analog Pain Scores)</measure>
    <time_frame>1 day following surgery</time_frame>
    <description>visual analog pain scores (scale 0=no pain; 10=worst pain imaginable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MS04 Equivalent Consumption</measure>
    <time_frame>1 day following surgery</time_frame>
    <description>in hospital total MS04 equivalent consumption</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>bupivacaine liposome suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bupivacaine liposome suspension periarticular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>concentrated multi drug injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>concentrated multi drug periarticular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine liposome suspension</intervention_name>
    <description>bupivacaine liposome suspension periarticular injection</description>
    <arm_group_label>bupivacaine liposome suspension</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL</intervention_name>
    <description>Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl</description>
    <arm_group_label>concentrated multi drug injection</arm_group_label>
    <other_name>Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  TKA candidacy

          -  Osteoarthritis

          -  Failure of non-operative treatments to control knee pain

          -  Patients able to understand and agree to study inclusion

        Exclusion Criteria:

          -  Subjects have orthopaedic and medical co-morbidities that would thwart postoperative
             pain control such as extra-articular pathology with referred pain to the knee (spinal
             stenosis, neuropathy,ipsilateral hip disease)

          -  Severe knee deformity

          -  Post-traumatic and inflammatory arthritis

          -  BMI above 40

          -  Patients unable to receive multimodal pain remitting agents

          -  Active knee sepsis

          -  Remote sites of active infection

          -  Diabetes with A1C &gt; 7

          -  ASA class &gt; lll

          -  Cardiac disease failing medical clearance

          -  Severe liver disease

          -  PAD with AAI &lt; 0.75

          -  Seizure disorder

          -  Allergic to any pain remitting agent

          -  Alcohol abuse

          -  Smoking abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2014</study_first_submitted>
  <study_first_submitted_qc>November 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2014</study_first_posted>
  <results_first_submitted>April 2, 2015</results_first_submitted>
  <results_first_submitted_qc>April 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 15, 2015</results_first_posted>
  <last_update_submitted>March 14, 2017</last_update_submitted>
  <last_update_submitted_qc>March 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bupivacaine Liposome Suspension</title>
          <description>bupivacaine liposome suspension periarticular injection
bupivacaine liposome suspension: bupivacaine liposome suspension periarticular injection</description>
        </group>
        <group group_id="P2">
          <title>Concentrated Multi Drug Injection</title>
          <description>concentrated multi drug periarticular injection
concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL: Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Men and women aged 18 and up receiving total knee arthroplasty for degenerative joint disease</population>
      <group_list>
        <group group_id="B1">
          <title>Bupivacaine Liposome Suspension</title>
          <description>bupivacaine liposome suspension periarticular injection
bupivacaine liposome suspension: bupivacaine liposome suspension periarticular injection</description>
        </group>
        <group group_id="B2">
          <title>Concentrated Multi Drug Injection</title>
          <description>concentrated multi drug periarticular injection
concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL: Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.3" spread="10.3"/>
                    <measurement group_id="B2" value="65.6" spread="7.9"/>
                    <measurement group_id="B3" value="66.4" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Scores (Visual Analog Pain Scores)</title>
        <description>visual analog pain scores (scale 0=no pain; 10=worst pain imaginable)</description>
        <time_frame>1 day following surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Liposome Suspension</title>
            <description>bupivacaine liposome suspension periarticular injection
bupivacaine liposome suspension: bupivacaine liposome suspension periarticular injection</description>
          </group>
          <group group_id="O2">
            <title>Concentrated Multi Drug Injection</title>
            <description>concentrated multi drug periarticular injection
concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL: Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores (Visual Analog Pain Scores)</title>
          <description>visual analog pain scores (scale 0=no pain; 10=worst pain imaginable)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="1.27"/>
                    <measurement group_id="O2" value="3.3" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MS04 Equivalent Consumption</title>
        <description>in hospital total MS04 equivalent consumption</description>
        <time_frame>1 day following surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Liposome Suspension</title>
            <description>bupivacaine liposome suspension periarticular injection
bupivacaine liposome suspension: bupivacaine liposome suspension periarticular injection</description>
          </group>
          <group group_id="O2">
            <title>Concentrated Multi Drug Injection</title>
            <description>concentrated multi drug periarticular injection
concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL: Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl</description>
          </group>
        </group_list>
        <measure>
          <title>MS04 Equivalent Consumption</title>
          <description>in hospital total MS04 equivalent consumption</description>
          <units>mg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="5.0" upper_limit="15.0"/>
                    <measurement group_id="O2" value="15.0" lower_limit="8.0" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bupivacaine Liposome Suspension</title>
          <description>bupivacaine liposome suspension periarticular injection
bupivacaine liposome suspension: bupivacaine liposome suspension periarticular injection</description>
        </group>
        <group group_id="E2">
          <title>Concentrated Multi Drug Injection</title>
          <description>concentrated multi drug periarticular injection
concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL: Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angela N Fellner PhD CCRP</name_or_title>
      <organization>TriHealth Hatton Research Institute</organization>
      <phone>513-862-2330</phone>
      <email>Angie_Fellner@trihealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

